Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Autologous hematopoietic stem cell transplantation for autoimmune diseases

Summary:

Experimental data and early phase I/II studies suggest that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) can arrest progression of severe autoimmune diseases. We have evaluated the toxicity and disease response in 473 patients with severe autoimmune disease treated with autologous HSCT between 1995 and 2003, from 110 centers participating in the European Group for Blood and Marrow Transplantation (EBMT) autoimmune disease working party database. Survival, transplant-related mortality, treatment response and disease progression were assessed. In all, 420 patients (89%; 86±4% at 3 years, median follow-up 20 months) were alive, 53 (11%) had died from transplant-related mortality (N=31; 7±3% at 3 years) or disease progression (N=22; 9±4% at 3 years). Of 370 patients, 299 evaluable for response (81%) showed a treatment response, which was sustained in 213 (71% of responders). Response was associated with disease (P<0.001), was better in patients who received cyclophosphamide during mobilization (relative risk (RR)3.28 (1.57–6.83)) and was worse with increasing age (>40 years, RR0.29 (0.11–0.82)). Disease progression was associated with disease (P<0.001) and conditioning intensity (high intensity, RR1; intermediate intensity, RR1.81 (0.96–3.42)); low intensity, RR2.34 (1.074–5.11)). These data from the collective EBMT experience support the hypothesis that autologous HSCT can alter disease progression in severe autoimmune disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Davidson A, Diamond B . Autoimmune diseases. N Engl J Med 2001; 345: 340–350.

    Article  CAS  Google Scholar 

  2. Gratwohl A, Passweg J, Gerber I, Tyndall A . Stem cell transplantation for autoimmune diseases. Best Pract Res Clin Haematol 2001; 14: 755–776.

    Article  CAS  Google Scholar 

  3. Marmont AM . Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 2004; 17: 223–232.

    Article  Google Scholar 

  4. van Bekkum DW . Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004; 17: 201–222.

    Article  CAS  Google Scholar 

  5. Ikehara S . Treatment of autoimmune diseases by hematopoietic stem cell transplantation. Exp Hematol 2001; 29: 661–669.

    Article  CAS  Google Scholar 

  6. Burt RK, Slavin S, Burns WH, Marmont AM . Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Int J Hematol 2002; 76 (Suppl. 1): 226–247.

    Article  Google Scholar 

  7. Marmont A, Tyndall A, Gratwohl A, Vischer T . Haemopoietic precursor-cell transplants for autoimmune diseases. Lancet 1995; 345: 978.

    Article  Google Scholar 

  8. Tyndall A, Gratwohl A . Haemopoietic stem and progenitor cells in the treatment of severe autoimmune diseases. Ann Rheum Dis 1996; 55: 149–151.

    Article  CAS  Google Scholar 

  9. Van Laar JM, Tyndall A . Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control 2003; 10: 57–65.

    Article  Google Scholar 

  10. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577–584.

    Article  CAS  Google Scholar 

  11. Farge D, Marolleau JP, Zohar S et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I–II study. Br J Haematol 2002; 119: 726–739.

    Article  Google Scholar 

  12. Fassas A, Passweg JR, Anagnostopoulos A et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002; 249: 1088–1097.

    Article  CAS  Google Scholar 

  13. Wulffraat NM, Sanders LA, Kuis W . Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2000; 2: 316–323.

    Article  CAS  Google Scholar 

  14. Traynor AE, Barr WG, Rosa RM et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002; 46: 2917–2923.

    Article  Google Scholar 

  15. Rosen O, Thiel A, Massenkeil G et al. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res 2000; 2: 327–336.

    Article  CAS  Google Scholar 

  16. Kashyap A, Passweg J, Tyndall A . Autologous hematopoietic stem cell transplant conditioning regimens for the treatment of severe autoimmune diseases. In: Dicke KA, Keating A (eds). Autologous Blood and Marrow Transplantation. Proceedings of the Ninth international Symposium. Carden Jennings Publishing: Arlington, Texas, Charlottesville, 2001.

    Google Scholar 

  17. Snowden JA, Passweg J, Moore JJ et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004; 31: 482–488.

    PubMed  Google Scholar 

  18. Wulffraat NM, Brinkman D, Ferster A et al. Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant 2003; 32 (Suppl. 1): S61–S64.

    Article  CAS  Google Scholar 

  19. Jayne D, Passweg J, Marmont A et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004; 13: 168–176.

    Article  Google Scholar 

  20. Huhn RD, Fogarty PF, Nakamura R et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003; 101: 71–77.

    Article  CAS  Google Scholar 

  21. Durez P, Toungouz M, Schandene L et al. Remission and immune reconstitution after T-cell-depleted stem-cell transplantation for rheumatoid arthritis. Lancet 1998; 352: 881.

    Article  CAS  Google Scholar 

  22. McColl G, Kohsaka H, Szer J, Wicks I . High-dose chemotherapy and syngeneic hemopoietic stem-cell transplantation for severe, seronegative rheumatoid arthritis. Ann Intern Med 1999; 131: 507–509.

    Article  CAS  Google Scholar 

  23. Verburg RJ, Kruize AA, van den Hoogen FH et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001; 44: 754–760.

    Article  CAS  Google Scholar 

  24. Kim KC, Lee IH, Choi JH et al. Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis. J Korean Med Sci 2002; 17: 129–132.

    Article  Google Scholar 

  25. Moore J, Brooks P, Milliken S et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301–2309.

    Article  CAS  Google Scholar 

  26. Lanza F, Dominici M, Govoni M et al. Prolonged remission state of refractory adult onset Still's disease following CD34-selected autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 25: 1307–1310.

    Article  CAS  Google Scholar 

  27. Wulffraat N, van Royen A, Bierings M et al. Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999; 353: 550–553.

    Article  CAS  Google Scholar 

  28. Quartier P, Prieur AM, Fischer A . Haemopoietic stem-cell transplantation for juvenile chronic arthritis. Lancet 1999; 353: 1885–1886.

    Article  CAS  Google Scholar 

  29. Tyndall A, Black C, Finke J et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997; 349: 254.

    Article  CAS  Google Scholar 

  30. Shaughnessy PJ, Ririe DW, Ornstein DL et al. Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue. Bone Marrow Transplant 2001; 27: 221–224.

    Article  CAS  Google Scholar 

  31. Wulffraat NM, Sanders EA, Kamphuis SS et al. Prolonged remission without treatment after autologous stem cell transplantation for refractory childhood systemic lupus erythematosus. Arthritis Rheum 2001; 44: 728–731.

    Article  CAS  Google Scholar 

  32. Myllykangas-Luosujarvi R, Jantunen E, Kaipiainen-Seppanen O et al. Autologous peripheral blood stem cell transplantation in a patient with severe mixed connective tissue disease. Scand J Rheumatol 2000; 29: 326–327.

    Article  CAS  Google Scholar 

  33. Baron F, Ribbens C, Kaye O et al. Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation. Br J Haematol 2000; 110: 339–342.

    Article  CAS  Google Scholar 

  34. Bingham S, Griffiths B, McGonagle D et al. Autologous stem cell transplantation for rapidly progressive Jo-1-positive polymyositis with long-term follow-up. Br J Haematol 2001; 113: 840–841.

    Article  CAS  Google Scholar 

  35. Fassas A, Anagnostopoulos A, Kazis A et al. Autologous stem cell transplantation in progressive multiple sclerosis – an interim analysis of efficacy. J Clin Immunol 2000; 20: 24–30.

    Article  CAS  Google Scholar 

  36. Carreras E, Saiz A, Marin P et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003; 88: 306–314.

    PubMed  Google Scholar 

  37. Openshaw H, Lund BT, Kashyap A et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000; 6: 563–575.

    Article  CAS  Google Scholar 

  38. Kozak T, Havrdova E, Pit'ha J et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000; 25: 525–531.

    Article  CAS  Google Scholar 

  39. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  CAS  Google Scholar 

  40. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.

    Article  CAS  Google Scholar 

  41. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  42. van Laar JM, McSweeney PA . High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis. Best Pract Res Clin Haematol 2004; 17: 233–245.

    Article  CAS  Google Scholar 

  43. Mancardi GL, Saccardi R, Filippi M et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001; 57: 62–68.

    Article  CAS  Google Scholar 

  44. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.

    Article  CAS  Google Scholar 

  45. Openshaw H, Stuve O, Antel JP et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000; 54: 2147–2150.

    Article  CAS  Google Scholar 

  46. Farge D, Passweg J, van Laar JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63: 974–981.

    Article  CAS  Google Scholar 

  47. Passweg JR, Rabusin M, Musso M et al. Haematopoietic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol 2004; 125: 749–755.

    Article  CAS  Google Scholar 

  48. Petri M, Jones RJ, Brodsky RA . High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 166–173.

    Article  CAS  Google Scholar 

  49. Storb RF, Lucarelli G, McSweeney PA, Childs RW . Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematology (Am Soc Hematol Educ Program) 2003; 1: 372–397.

    Article  Google Scholar 

  50. Tisdale JF, Dunn DE, Geller N et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000; 356: 1554–1559.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the participating centres, the support of the project by the EBMT corporate members (Amgen Europe, Hoffmann-La Roche Ltd, Gilead Sciences, Baxter Oncology, Pharmacia Corporation, Chugai-Aventis, Fresenius HemoCare, SangStat, Schering AG, Gambro BCT, Elan Pharmaceuticals, Miltenyl Biotec GmbH, Therakos, Wyeth-Lederlé, Astra, Cobe International, Nextar, Liposome Co., Imtix, the Horton Foundation, the Swiss National Research Foundation, the Regional Cancer League Basel and the Délégation Régionale à la Recherche Clinique (DRRC), Assistance Publique-Hôpitaux de Paris (AP-HP), the French Ministry of Health (Programme Hospitalier de Recherche Clinique: PHRC 1997 AOM 97-030) and Professor E Gluckman, Hôpital St Louis, Paris).

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to A Tyndall.

Appendix A1

Appendix A1

List of participating centers:

Austria: Vienna, Vienna University Hospital; Australia: Brisbane, Mater Hospital; Hobart, Royal Hobart Hospital; Melbourne, Royal Melbourne Hospital; Perth, Sir Charles Gairdner Hospital; Royal Perth Hospital; Sydney, St Vincent's Hospital; Belgium: Brussels, Children University Hospital, Erasmus Hospital, Institut Jules Bordet; Liège, Centre Hospitalier Universitaire; Leuven, University Hospital Gasthuisberg; China: Nanjing, Gu Lou Hospital; Peking, Peking University Medical Center Hospital; Zhengzhou, The Third People Hospital of Zhengzhou; Czech Republic: Pilsen, Charles University Hospital; Prague, University Hospital Kralovske Vinohrady, University Hospital Motol; Finland: Kuopio, Kuopio University Hospital; Turku, Turku University Central Hospital; France: Besançon, Hôpital Jean Minijoz; Brest, Hôpital Morvan; Clermont Ferrant, Centre Hospitalier Universitaire; Lille, Hôpital Claude Huriez; Limoges, Centre Hospitalier Regional Universitaire Limoges; Marseilles, Institut Paoli Calmettes; Paris, Centre Hospitalier Universitaire Cochin, Hôpital Necker, Hôpital St Antoine, Hôpital St Louis, Pitie-Salpetriere; Strassbourg, Hôpital Universitaire de Hautepierre; Toulouse, Hôpital de Purpan; Germany: Berlin, Universitätsklinikum Charité, Charité-Virchow Klinikum; Bochum, University Hospital Knappschfts-Krankenhaus; Dresden, Universitätsklinikum; Düsseldorf, Henrich Heine Universität; Erlangen, University Hospital; Frankfurt, Universitätsklinikum; Freiburg, Klinikum der Albert-Ludwigs Universität Freiburg; Halle, Martin-Luther-Universität; Hannover, Medizinische Hochschule; Heidelberg, University of Heidelberg; Jena, University of Jena; Münster, Universitätsklinik; Tübingen, Medizinische Universitätsklinik; Wiesbaden, Deutsche Zentrum für Krankeitsdiagnostik; Hungary: Miskolc, Postgraduate Medical School; Greece: Thessaloniki, George Papanicolaou Hospital; Israel: Haifa, Rambam Medical Center; Jerusalem, Hadassah University Hospital; Italy: Cagliari, University of Cagliari; Ferrara, Ospedale St Anna; Firenze, Ospedale di Careggi, Ospedale Pediatrico ‘A.Meyer’; Genova, Ospedale San Martino; Milano, Ospedale San Raffaele; Modena, University of Modena; Monza, Ospedale San Gerardo; Torino, Ospedale San Luigi Orbassano; Padova, University Hospital; Palermo, Ospedale Oncologico ‘La Maddalena’; Pavia, Policlinico San Matteo; Pescara, Ospedale Civile; Pisa, University of Pisa; Reggio Emilia, Arcispedale Santa Maria Nuova; Reggio Calabria, Azienda Ospedaliera Bianchi-Melacrino-Morelli; Roma, Ospedale San Camillo, Università ‘La Sapienza’, Università Tor Vergata; Trieste, Istituto per l’Infanzia Burlo Garofolo; Udine, University Hospital; Japan: Osaka, Osaka Medical Center; The Netherlands: Leiden, Leiden University Medical Center; Nijmegen, University Medical Center St Radboud; Rotterdam, Erasmus University Medical Center; Utrecht, University Medical Center; Poland: Poznan, K. Marcinkowski University; Russia: Novosibirsk, Institute of Clinical Immunology; St Petersburg, St Petersburg State I. Pavlov Medical University; Slovakia: Bratislava, University Hospital; Spain: Barcelona, Hospital Clinic, Hospital Santa Creu i Sant Pau, Hospital Vall d'Hebron; Cádiz , Hospital del SAS; Lugo, Hospital Xeral-Calde; Madrid, Clinica Puerta de Hierro, Hospital Infantil La Paz, Hospital G.U. Gregorio Maranon, Hospital de la Princesa; Malaga, Hospital Carlos Haya; Palma de Mallorca, Hospital San Dureta; Santander, Hospital Universitario ‘Marquéz de Valdecilla’; Sevilla, Hospital Universitario Virgen del Rocio; Valencia, Hospital Clinico Universitario; Sweden: Göteborg, Sahlgrenska University Hospital; Lund, University Hospital; Uppsala, University Hospital; Switzerland: Basel, Kantonsspital; Zürich, University Children Hospital; UK: Birmingham, University of Birmingham; Leeds, University of Leeds; Liverpool, Royal Liverpool University Hospital; London, Great Ormond Street Hospital, Hammersmith Hospital, Royal Free Hospital, St George's Hospital, University College Hospital; Newcastle, Royal Victoria Infirmary; Nottingham, Nottingham City Hospital.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gratwohl, A., Passweg, J., Bocelli-Tyndall, C. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 35, 869–879 (2005). https://doi.org/10.1038/sj.bmt.1704892

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704892

Keywords

This article is cited by

Search

Quick links